Sulfonamide Derivatives for the Treatment of Bacterial Infections

1 - 23 . (canceled)

24 . A method of treating a bacterial infection comprising the administration, to an individual in need of treatment, a composition comprising a sulfonamide derivative according to Formula (I),

wherein:

G 1 is selected from —CR 6 R 7 —, —O—, —S— or —N(R 8 );

R 1 is selected from H, C 1 -C 6 alkyl, C 7 -C 12 -alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, aryl C 1 -C 6 alkyl, heteroaryl C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl C 1 -C 6 alkyl or heteroaryl C 1 -C 6 alkyl;

R 2 is selected from H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl or C 3 -C 8 cycloalkyl;

R 3 and R 4 are independently selected from H, C 1 -C 6 alkyl or halogen;

R 5 is selected from H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl or C 3 -C 8 cycloalkyl;

R 6 , R 7 and R 8 are independently selected from H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl;

Cy is selected from aryl, heteroaryl, C 3 -C 8 cycloalkyl or heterocycloalkyl; and

m and n are integers independently selected from 0, 1, 2, 3 or 4;

or geometrical isomers, enantiomers, diastereomers, racemates, or pharmaceutically acceptable salts thereof.

25 . The method according to claim 24 , wherein G 1 is —S—.

26 . The method according to claim 24 , wherein R 1 is selected from C 1 -C 6 alkyl, C 7 -C 12 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl.

27 . The method according to claim 24 , wherein R 1 is selected from optionally substituted aryl C 1 -C 6 alkyl or optionally substituted heteroaryl C 1 -C 6 alkyl.

28 . The method according to claim 24 , wherein R 2 is H.

29 . The method according to claim 24 , wherein R 3 is H.

30 . The method according to claim 24 , wherein R 4 is H.

31 . The method according to claim 24 , wherein R 5 is H.

32 . The method according to claim 24 , wherein R 6 is H.

33 . The method according to claim 24 , wherein R 7 is H.

34 . The method according to claim 24 , wherein m is 0.

35 . The method according to claim 24 , wherein m is 1.

36 . The method according to claim 24 , wherein n is 1.

37 . The method according to claim 24 , wherein R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are H; m is selected from 0 and 1; n is 1; G 1 is S; and R 1 and Cy are as described in claim 24 .

38 . The method according to claim 24 , wherein the compound of Formula (J) is selected from:

{({5-[(dodecylamino)sulfonyl]-2-thienyl}methyl)[4-(trifluoromethyl)benzyl]amino}(oxo)acetic acid;

[benzyl({5-[(dodecylamino)sulfonyl]-2-thienyl}methyl)amino](oxo)acetic acid;

[cyclopentyl({5-[(dodecylamino)sulfonyl]-2-thienyl}methyl)amino](oxo)acetic acid;

[({5-[(dodecylamino)sulfonyl]-2-thienyl}methyl)(3-nitrobenzyl)amino](oxo)acetic acid;

[({5-[(dodecylamino)sulfonyl]-2-thienyl}methyl)(4-methoxybenzyl)amino](oxo) acetic acid;

[({5-[(dodecylamino)sulfonyl]-2-thienyl}methyl)(2-fluorobenzyl)amino](oxo)acetic acid;

{({5-[(dodecylamino)sulfonyl]-2-thienyl}methyl)[4-(methylsulfonyl)benzyl]amino}(oxo)acetic acid;

[({5-[(dodecylamino)sulfonyl]-2-thienyl}methyl)(4-phenoxybenzyl)amino](oxo) acetic acid;

4-{[(carboxycarbonyl)({5-[(dodecylamino)sulfonyl]-2-thienyl}methyl)amino]methyl}benzoic acid;

(({5-[(dodecylamino)sulfonyl]-2-thienyl}methyl) {[6-(trifluoromethyl)pyridin-3-yl]methyl}amino)(oxo)acetic acid;

{({5-[(dodecylamino)sulfonyl]-2-thienyl}methyl) [3-(trifluoromethyl)benzyl]amino}(oxo)acetic acid;

[(3-chlorobenzyl)({5-[(dodecylamino)sulfonyl]-2-thienyl}methyl)amino](oxo)acetic acid;

{[(5-{[(3,3-diphenylpropyl)amino]sulfonyl}-2-thienyl)methyl][3-(trifluoromethyl)benzyl]amino}(oxo)acetic acid;

{(3-chlorobenzyl)[(5-{[(3,3-diphenylpropyl)amino]sulfonyl}-2-thienyl)methyl]amino}(oxo)acetic acid;

oxo {{[5-({[2-(4-phenoxyphenyl)ethyl]amino}sulfonyl)-2-thienyl]methyl}[3-(trifluoromethyl)benzyl]amino}acetic acid;

((3-chlorobenzyl) {[5-({[2-(4-phenoxyphenyl)ethyl]amino}sulfonyl)-2-thienyl]methyl}amino)(oxo)acetic acid;

{[(5-{[(2-biphethyl-4-ylethyl)amino]sulfonyl}-2-thienyl)methyl][3-(trifluoromethyl)benzyl]amino}(oxo)acetic acid;

{({5-[(hexylamino)sulfonyl]-2-thienyl}methyl) [3-(trifluoromethyl)benzyl]amino}(oxo)acetic acid;

{({5-[(hexylamino)sulfonyl]-2-thienyl}methyl) [3-(trifluoromethyl)benzyl]amino}(oxo)acetic acid;

[[(5-{[(2-biphenyl-4-ylethyl)amino]sulfonyl}-2-thienyl)methyl](pyridin-4-ylmethyl)amino](oxo)acetic acid;

4-({[5-({(carboxycarbonyl)[3-(trifluoromethyl)benzyl]amino}methyl)-2-thienyl]sulfonyl}amino)butanoic acid;

4-{[(5-{[(carboxycarbonyl)(3-chlorobenzyl)amino]methyl}-2-thienyl)sulfonyl]amino}butanoic acid;

{{[5-({[2-(4-chlorophenyl)propyl]amino}sulfonyl)-2-thienyl]methyl}[3-(trifluoromethyl)benzyl]amino}(oxo)acetic acid;

[{[5-({[2-(4-chlorophenyl)propyl]amino}sulfonyl)-2-thienyl]methyl}(pyridin-4-yl methyl)amino](oxo)acetic acid;

((3-chlorobenzyl) {[5-({[2-(4-chlorophenyl)propyl]amino}sulfonyl)-2-thienyl]methyl}amino)(oxo)acetic acid;

{[(5-{[(2-ethylhexyl)amino]sulfonyl}-2-thienyl)methyl][3-(trifluoromethyl)benzyl]amino}(oxo)acetic acid;

[[(5-{[(2-ethylhexyl)amino]sulfonyl}-2-thienyl)methyl](pyridin-4-ylmethyl)amino](oxo)acetic acid;

{(3-chlorobenzyl) [(5-{[(2-ethylhexyl)amino]sulfonyl}-2-thienyl)methyl]amino}(oxo)acetic acid; or

((3-chlorobenzyl) {[5-({[2-({[5-(dimethylamino)-1-naphthyl]sulfonyl}amino)ethyl]amino}sulfonyl)-2-thienyl]methyl}amino)(oxo)acetic acid.

39 . A method of inhibiting the activity of a Mycobacterium tuberculosis Protein Tyrosine Phosphatase (MPTP) comprising contacting M. tuberculosis with a compound Of Formula (I)

wherein:

G 1 is selected from —CR 6 R 7 —, —O—, —S— or —N(R 8 );

R 1 is selected from H, C 1 -C 6 alkyl, C 7 -C 12 -alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, aryl C 1 -C 6 alkyl, heteroaryl C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl C 1 -C 6 alkyl or heteroaryl C 1 -C 6 alkyl;

R 2 is selected from H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl or C 3 -C 8 cycloalkyl;

R 3 and R 4 are independently selected from H, C 1 -C 6 allyl or halogen;

R 5 is selected from H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl or C 3 -C 8 cycloalkyl;

R 6 , R 7 and R 8 are independently selected from H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl;

Cy is selected from aryl, heteroaryl, C 3 -C 8 cycloalkyl or heterocycloalkyl; and

m and n are integers independently selected from 0, 1, 2, 3 and 4;

or geometrical isomers, enantiomers, diastereomers, racemates, or pharmaceutically acceptable salts thereof.

40 . A compound selected from:

[[(5-{[(2-biphenyl-4-ylethyl)amino]sulfonyl}-2-thienyl)methyl](pyridin-4-ylmethyl)amino](oxo)acetic acid:

4-({[5-({(carboxycarbonyl) [3-(trifluoromethyl)benzyl]amino}methyl)-2-thienyl]sulfonyl}amino)butanoic acid;

4-{[(5-{[(carboxycarbonyl)(3-chlorobenzyl)amino]methyl}-2-thienyl)sulfonyl]amino}butanoic acid;

{{[5-({[2-(4-chlorophenyl)propyl]amino}sulfonyl)-2-thienyl]methyl}[3-(trifluoromethyl)benzyl]amino}(oxo)acetic acid;

[{[5-({[2-(4-chlorophenyl)propyl]amino}sulfonyl)-2-thienyl]methyl}(pyridin-4-ylmethyl)amino](oxo)acetic acid;

((3-chlorobenzyl){[5-({[2-(4-chlorophenyl)propyl]amino}sulfonyl)-2-thienyl]methyl}amino)(oxo)acetic acid;

{[(5-{[(2-ethylhexyl)amino]sulfonyl}-2-thienyl)methyl][3-(trifluoromethyl)benzyl]amino}(oxo)acetic acid;

[[(5-{[(2-ethylhexyl)amino]sulfonyl}-2-thienyl)methyl](pyridin-4-ylmethyl)amino](oxo)acetic acid;

{(3-chlorobenzyl)[(5-{[(2-ethylhexyl)amino]sulfonyl}-2-thienyl)methyl]amino}(oxo)acetic acid; or

((3-chlorobenzyl) {[5-({[2-({[5-(dimethylamino)-1-naphthyl]sulfonyl}amino)ethyl]amino}sulfonyl)-2-thienyl]methyl}amino)(oxo)acetic acid.

41 . A pharmaceutical composition comprising a compound according to claim 40 and a pharmaceutically acceptable carrier, diluent or excipient thereof.

42 . A process for the preparation of a compound comprising reacting an amine of Formula (II) with a carboxylic acid derivative of Formula LG 2 -CO—CO—R 2

wherein:

R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , m, G 1 and Cy are as described in claim 24 , n is 1 and LG 2 is a leaving group selected from Cl, N-hydroxy succinimide or benzotriazol-1-yl.

43 . A derivative of Formula (II) selected from:

Ethyl {({5-[(hexylamino)sulfonyl]-2-thienyl}methyl) [3 (trifluoromethyl)benzyl]amino}(oxo)acetate;

Ethyl [[(5-{[(2-biphenyl-4-ylethyl)amino]sulfonyl}-2-thienyl)methyl](pyridin-4-ylmethyl)amino](oxo)acetate;

4-({[5-({[ethoxy(oxo)acetyl][3-(trifluoromethyl)benzyl]amino}methyl)-2-thienyl]sulfonyl}amino)butanoic acid;

4-({[5-({(3-chlorobenzyl) [ethoxy(oxo)acetyl]amino}methyl)-2-thienyl]sulfonyl}amino)butanoic acid;

Ethyl {{[5-({[2-(4-chlorophenyl)propyl]amino}sulfonyl)-2-thienyl]methyl}[3-(trifluoromethyl)benzyl]amino}(oxo)acetate;

Ethyl [{[5-({[2-(4-chlorophenyl)propyl]amino}sulfonyl)-2-thienyl]methyl}(pyridin-4-ylmethyl)amino](oxo)acetate;

Ethyl ((3-chlorobenzyl){[5-({[2-(4-chlorophenyl)propyl]amino}sulfonyl)-2-thienyl]methyl}amino)(oxo)acetate:

Ethyl {[(5-{[(2-ethylhexyl)amino]sulfonyl}-2-thienyl)methyl][3-(trifluoromethyl)benzyl]amino}(oxo)acetate:

Ethyl [[(5-{[(2-ethylhexyl)amino]sulfonyl}-2-thienyl)methyl](pyridin-4-ylmethyl)amino](oxo)acetate;

Ethyl {(3-chlorobenzyl)[(5-{[(2-ethylhexyl)amino]sulfonyl}-2-thienyl)methyl]amino}(oxo)acetate; or

Ethyl ((3-chlorobenzyl) {[5-({[2-({[5-(dimethylamino)-1-naphthyl]sulfonyl}amino)ethyl]amino}sulfonyl)-2-thienyl]methyl}amino)(oxo)acetate.